Does Use of Bilateral Internal Mammary Artery Grafting Reduce Long-Term Risk of Repeat Coronary Revascularization?

Ovid Technologies (Wolters Kluwer Health) - Tập 136 Số 18 - Trang 1676-1685 - 2017
Alexander Iribarne1, Joseph Schmoker1, David J. Malenka1, Bruce J. Leavitt1, Jock N. McCullough1, Paul W. Weldner1, Joseph P. DeSimone1, Benjamin M. Westbrook1, Reed D. Quinn1, John D. Klemperer1, Gerald L. Sardella1, Robert S. Kramer1, Elaine M. Olmstead1, Anthony W. DiScipio1
1From Department of Surgery, Section of Cardiac Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH (A.I., D.J.M., J.N.M., J.P.D., E.M.O., A.W.D.); Department of Medicine, Section of Cardiology, Dartmouth-Hitchcock Medical Center, Lebanon, NH (D.J.M.); Department of Surgery, Section of Cardiac Surgery, University of Vermont Medical Center, Burlington (J.D.S., B.J.L.); Department of Surgery, Section of Cardiac Surgery, Central Maine Medical Center, Lewiston (P.W.W.); Department of Surgery,...

Tóm tắt

Background: Although previous studies have demonstrated that patients receiving bilateral internal mammary artery (BIMA) conduits during coronary artery bypass grafting have better long-term survival than those receiving a single internal mammary artery (SIMA), data on risk of repeat revascularization are more limited. In this analysis, we compare the timing, frequency, and type of repeat coronary revascularization among patients receiving BIMA and SIMA. Methods: We conducted a multicenter, retrospective analysis of 47 984 consecutive coronary artery bypass grafting surgeries performed from 1992 to 2014 among 7 medical centers reporting to a prospectively maintained clinical registry. Among the study population, 1482 coronary artery bypass grafting surgeries with BIMA were identified, and 1297 patients receiving BIMA were propensity-matched to 1297 patients receiving SIMA. The primary end point was freedom from repeat coronary revascularization. Results: The median duration of follow-up was 13.2 (IQR, 7.4–17.7) years. Patients were well matched by age, body mass index, major comorbidities, and cardiac function. There was a higher freedom from repeat revascularization among patients receiving BIMA than among patients receiving SIMA (hazard ratio [HR], 0.78 [95% CI, 0.65–0.94]; P =0.009). Among the matched cohort, 19.4% (n=252) of patients receiving SIMA underwent repeat revascularization, whereas this frequency was 15.1% (n=196) among patients receiving BIMA ( P =0.004). The majority of repeat revascularization procedures were percutaneous coronary interventions (94.2%), and this did not differ between groups ( P =0.274). Groups also did not differ in the ratio of native versus graft vessel percutaneous coronary intervention ( P =0.899), or regarding percutaneous coronary intervention target vessels; the most common targets in both groups were the right coronary ( P =0.133) and circumflex arteries ( P =0.093). In comparison with SIMA, BIMA grafting was associated with a reduction in all-cause mortality at 12 years of follow-up (HR, 0.79 [95% CI, 0.69–0.91]; P =0.001), and there was no difference in in-hospital morbidity. Conclusions: BIMA grafting was associated with a reduced risk of repeat revascularization and an improvement in long-term survival and should be considered more frequently during coronary artery bypass grafting.

Từ khóa


Tài liệu tham khảo

10.1016/j.athoracsur.2016.11.001

10.1016/j.jacc.2016.06.021

10.1056/NEJMoa1211585

10.1001/jamainternmed.2013.12844

10.1093/eurheartj/ehr213

10.1016/j.jtcvs.2014.06.086

10.1016/S0003-4975(01)03339-2

10.1097/01.hco.0000182833.26273.f1

10.4244/EIJV9I8A151

10.1161/01.CIR.48.1S3.III-190

10.1016/S0003-4975(10)60684-4

10.1161/CIRCULATIONAHA.113.004255

10.3978/j.issn.2225-319X.2013.07.16

10.1016/j.jtcvs.2014.01.010

10.1016/S1010-7940(02)00470-0

10.1016/j.jtcvs.2011.10.029

10.1136/heartjnl-2013-303961

10.1016/j.athoracsur.2012.11.068

10.1016/j.jtcvs.2004.07.059

10.1056/NEJMoa1610021

10.1016/0003-4975(92)90346-6

10.1016/j.jtcvs.2003.10.006

10.1016/j.athoracsur.2006.10.032

10.1016/j.athoracsur.2010.04.006

10.1016/S0022-5223(19)36947-8

10.1056/NEJM198808253190802

10.1016/j.ygeno.2014.04.005

10.1016/j.jtcvs.2009.05.033

10.1016/j.athoracsur.2011.03.099

10.1016/j.athoracsur.2015.02.088

10.1161/CIRCULATIONAHA.112.117606

10.1016/S0022-5223(99)70365-X

10.1016/j.ejcts.2004.05.028

10.1016/0003-4975(96)00627-3

10.1161/hc4301.098283

10.1016/j.athoracsur.2015.09.100

10.1093/eurheartj/ehq318

10.1186/1745-6215-7-7

10.1093/eurheartj/ehu213

10.1016/j.jacc.2015.07.060

10.1016/j.jtcvs.2016.03.022

10.1016/j.athoracsur.2011.01.055

10.1161/CIRCULATIONAHA.107.760827

Thông tin
Thông tin xuất bản

Ovid Technologies (Wolters Kluwer Health)

Tập 136 Số 18

1676-1685

Thông tin tác giả